Abstract
Background:
Hyperuricemia may play a role in various systemic diseases. However, few studies have investigated the relationship between hyperuricemia and the risk of peptic ulcer disease (PUD). Therefore, in this population-based study, we enrolled over 120,000 participants from the Taiwan Biobank (TWB) and examined the risk factors for self-reported PUD. In addition, we investigated sex differences in the association between hyperuricemia and self-reported PUD.
Methods:
Data of 121,583 participants were obtained from the TWB. Male participants with a serum uric acid level >7 mg/dl and female participants with a serum uric acid level >6 mg/dl were classified as having hyperuricemia. Details of self-reported PUD were obtained by questionnaire. The association between hyperuricemia and self-reported PUD in the male and female participants was examined using multivariable logistic regression analysis.
Results:
The overall prevalence of self-reported PUD was 14.6%, with a higher incidence in males (16.5%) compared to females (13.5%). After multivariable adjustment, male sex [vs. female sex; odds ratio (OR) = 1.139; 95% confidence interval (CI) = 1.084–1.198; p < 0.001], and hyperuricemia (OR = 0.919; 95% CI = 0.879–0.961; p < 0.001) were significantly associated with self-reported PUD. Further, a significant interaction was found between sex and hyperuricemia on self-reported PUD (p = 0.004). Hyperuricemia was associated with a low risk of self-reported PUD in males (OR = 0.890; 95% CI = 0.837–0.947; p < 0.001) but not in females (p = 0.139).
Conclusion:
The prevalence of self-reported PUD was higher in the male participants than in the female participants. Hyperuricemia was associated with low prevalence of self-reported PUD in males, but not in females. Further studies are needed to clarify the mechanisms behind these observations and verify the potential protective role of hyperuricemia on the development of self-reported PUD.
Introduction
Peptic ulcer disease (PUD) is defined as a mucosa defect greater than 3–5 mm extending through the muscularis mucosa over the gastrointestinal tract, although it usually presents in the stomach and proximal duodenum (1). A 2020 study, which analyzed PUD burden according to the Global Burden of Disease, Injuries and Risk Factors Study, estimated that there were 8.09 million prevalent cases in 2019 globally (2). A 2004 prospective study in Taiwan of 6,457 subjects who underwent esophagogastroduodenoscopy during a health examination found that two-thirds of the patients diagnosed with PUD endoscopically were asymptomatic (3). PUD is associated with Helicobacter pylori infection (4) and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (5), and additional risk factors include advanced age, smoking, and alcoholism (6, 7). These factors may influence various aspects of gastrointestinal physiology, such as gastric acid secretion and mucosal defense mechanisms, ultimately contributing to the development of PUD (8). Sex differences have been observed in many diseases, including cancer, liver and cardiovascular diseases, and these differences can have an essential influence on the clinical presentation, disease progression, and response to treatment (9). While PUD was predominantly observed in males in the past, there has been a shift from a male-dominated pattern in Western countries to a nearly equal prevalence between males and females (10). PUD can lead to serious complications such as acute upper gastrointestinal bleeding, perforation, gastric outlet obstruction, and even mortality (11). Therefore, identifying risk factors which may be associated with PUD is important to decrease healthcare system burden and prompt the development of new treatment strategies for improving patient care.
Hyperuricemia is a chronic disease caused by high levels of uric acid due to conditions including dysfunctional purine metabolism and a reduction in the excretion of uric acid (12, 13). Purine metabolism to uric acid occurs through the catalyzation of hypoxanthine to xanthine by xanthine oxidase (14). Moreover, the reactive oxygen species generated during this process have been shown to contribute to metabolic dysfunction (14). These mechanisms imply that hyperuricemia may play a role in various systemic diseases. Associations between hyperuricemia and a higher risk of gout (15) and cardiovascular issue such as hypertension, low left ventricular ejection fraction, and high left atrial diameter have been reported (16, 17), along with dyslipidemia, thyroid dysfunction, chronic kidney disease, and metabolic syndrome (15, 16, 18, 19). However, several studies have suggested that hyperuricemia or gout might act as a protective factor against neurodegenerative diseases such as Alzheimer’s disease or neurological functional outcomes after an acute ischemic stroke (20–22). Nevertheless, some studies have reported conflicting results (23), and the same debate has arisen in the context of osteoporosis and hyperuricemia. Some studies have indicated that individuals with normal or elevated levels of uric acid were associated with a decrease in bone mineral density and lower risk of bone fractures (24). Other studies have demonstrated that elevated levels of serum uric acid were linked to increased bone mass, reduced bone turnover, and a lower incidence of vertebral fractures in postmenopausal women (25). Recent studies have reported that the intestine may play a crucial role in the excretion of uric acid outside the kidneys (26). However, few studies have investigated the relationship between hyperuricemia and the risk of PUD. Therefore, in this population-based study, we enrolled over 120,000 participants from the Taiwan Biobank (TWB) and examined the risk factors for self-reported PUD. In addition, we investigated sex differences in the association between hyperuricemia and self-reported PUD.
Materials and methods
TWB
To enhance biomedical and epidemiological research and address the aging population in Taiwan, the TWB is an ongoing prospective study launched by the Ministry of Health and Welfare in 2012 of community-dwelling cancer-free women and men (27, 28). Ethical approval for the TWB was given by the Ethics and Governance Council of the TWB and Institutional Review Board on Biomedical Science Research, Academia Sinica, Taiwan.
The TWB contains medical, genomic and lifestyle factor data, including age, weight, height, and diagnoses of hypertension and diabetes mellitus (DM). In addition, laboratory tests on fasting serum samples (Roche Diagnostics GmbH, D-68298 Mannheim COBAS Integra 400) are conducted to collect data on glucose, hemoglobin, triglycerides, total cholesterol, high- and low-density lipoprotein cholesterol (HDL-C/LDL-C), and uric acid. Estimated glomerular filtration rate (eGFR) and serum creatinine levels were calculated as reported in previous studies (29).
The average of three blood pressure measurements was used for analysis, with each measurement being performed in the absence of caffeine, nicotine and exercise by a nurse using an electronic monitor. Regular exercise was defined according to the “Physical Fitness 333 Plan” in Taiwan as at least three sessions of exercise per week with each session lasting at least 30 min (30). This study complies with the Declaration of Helsinki and was performed according to institutional review board approval (KMUHIRB-E(I)-20210058).
Sample population and sample size
The TWB enrolls cancer-free members of the community aged 30–70 years, and includes data on medical, genetic, and lifestyle factors. We collected 121,583 enrollees in the TWB. These participants were then classified into those with and without hyperuricemia based on a serum uric acid concentration of >7.0 and >6.0 mg/dl in males and females, respectively (31) (Figure 1).
FIGURE 1
Flowchart of study population.
Definitions of self-reported PUD
A history of self-reported PUD was recorded using self-reported questionnaires. The presence of self-reported PUD was defined by asking the participants whether they a history of PUD.
Statistical analysis
The statistical analyses in this study were performed using SPSS version 19.0 for Windows (IBM Inc., Armonk, NY, USA). Continuous variables were expressed as mean ± standard deviation, and between-group differences were analyzed using the independent t-test. Categorical variables were presented as frequencies and percentages, and between-group differences were analyzed using the Chi-square test. Associations between hyperuricemia and self-reported PUD in the male and female participants were examined using multivariable logistic regression analysis, which included significant variables in univariable analysis. An interaction p in logistic analysis: Model disease (y) = x1 + x2 + x1 × x2 + covariates. x1 × x2 was the interaction term, in which y = self-reported PUD; x1 = sex; x2 = hyperuricemia; covariates = age, sex, DM, hypertension, smoking and alcohol history, regular exercise habit, systolic blood pressure (SBP), body mass index (BMI), hyperuricemia, fasting glucose, hemoglobin, triglycerides, total cholesterol, LDL-cholesterol, and eGFR. A two-tailed p-value < 0.05 was considered statistically significant.
Results
Of the 121,583 participants, 43,698 were male and 77,885 were female, with a mean age of 49.9 ± 11.0 years. The overall prevalence of self-reported PUD in the study cohort was 14.6%, and the difference between the male and female participants was significant (16.5% vs. 13.5%, p < 0.001).
Comparison of the participants with and without self-reported PUD
Table 1 shows the comparisons of the participants with and without self-reported PUD. The participants in the self-reported PUD group were older, predominantly female, and had higher rates of DM, hypertension, smoking and alcohol consumption, regular exercise, and higher SBP, uric acid, hemoglobin, triglycerides, total cholesterol, and LDL-C, and lower BMI, eGFR and fasting glucose compared to those without self-reported PUD (Table 1).
TABLE 1
| Characteristics | Self-reported PUD (n = 121,583) | ||
| Self-reported PUD (−) (n = 103,887) |
Self-reported PUD (+) (n = 17,696) |
p | |
| Age (year) | 49.3 ± 11.0 | 53.2 ± 1.01 | <0.001 |
| Male sex (%) | 35.1 | 40.7 | <0.001 |
| DM (%) | 4.9 | 6.7 | <0.001 |
| Hypertension (%) | 11.7 | 15.6 | <0.001 |
| Smoking history (%) | 26.4 | 32.6 | <0.001 |
| Alcohol history (%) | 8.2 | 10.3 | <0.001 |
| Regular exercise habits (%) | 39.9 | 44.5 | <0.001 |
| Systolic BP (mmHg) | 120.3 ± 18.7 | 121.1 ± 18.3 | <0.001 |
| Diastolic BP (mmHg) | 73.8 ± 11.4 | 73.9 ± 11.1 | 0.076 |
| BMI (kg/m2) | 24.2 ± 3.8 | 24.1 ± 3.7 | <0.001 |
| Laboratory parameters | |||
| Uric acid (mg/dl) | 5.42 ± 1.43 | 5.46 ± 1.40 | <0.001 |
| Hyperuricemia (%) | 19.5% | 19.0% | 0.199 |
| Fasting glucose (mg/dl) | 95.8 ± 20.8 | 86.8 ± 19.9 | <0.001 |
| Hemoglobin (g/dl) | 13.7 ± 1.6 | 13.9 ± 1.6 | <0.001 |
| Triglyceride (mg/dl) | 115.2 ± 94.8 | 117.8 ± 89.0 | 0.001 |
| Total cholesterol (mg/dl) | 195.5 ± 35.9 | 196.6 ± 35.6 | <0.001 |
| HDL-C (mg/dl) | 54.6 ± 13.4 | 54.4 ± 13.7 | 0.111 |
| LDL-C (mg/dl) | 120.8 ± 31.8 | 121.5 ± 31.6 | 0.007 |
| eGFR (ml/min/1.73 m2) | 103.8 ± 23.9 | 100.4 ± 23.6 | <0.001 |
Clinical characteristics of the study participants classified by the presence of self-reported PUD.
Hyperuricemia was defined as serum uric acid concentration greater than 7.0 and 6.0 mg/dl in the male and female participants, respectively. PUD, peptic ulcer disease; DM, diabetes mellitus; BP, blood pressure; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate.
Factors associated with self-reported PUD
Table 2 shows the factors associated with self-reported PUD. The results of multivariable logistic regression analysis with adjustments for the covariates listed in section “Statistical analysis” showed that older age (p < 0.001), male sex [vs. female sex; odds ratio (OR) = 1.139, 95% confidence interval (CI) = 1.084–1.198, p < 0.001], DM (p = 0.001), hypertension (p < 0.001), smoking history (p < 0.001), alcohol history (p < 0.001), without regular exercise habits (p < 0.001), low SBP (p < 0.001), low BMI (p < 0.001), without hyperuricemia (OR = 0.919; 95% CI = 0.879–0.961, p < 0.001), low fasting glucose (p < 0.001), and high hemoglobin (p = 0.019) were significantly associated with self-reported PUD (Table 2).
TABLE 2
| Variables | Multivariable (self-reported PUD) | |
| Odds ratio (95% CI) | p | |
| Age (per 1 year) | 1.038 (1.036–1.040) | <0.001 |
| Male (vs. female) | 1.139 (1.084–1.198) | <0.001 |
| DM | 1.142 (1.058–1.273) | 0.001 |
| Hypertension | 1.160 (1.103–1.220) | <0.001 |
| Smoking history | 1.286 (1.232–1.342) | <0.001 |
| Alcohol history | 1.113 (1.051–1.179) | <0.001 |
| Regular exercise habits | 0.939 (0.907–0.972) | <0.001 |
| Systolic BP (per 1 mmHg) | 0.993 (0.992–0.994) | <0.001 |
| BMI (per 1 kg/m2) | 0.982 (0.977–0.987) | <0.001 |
| Laboratory parameters | ||
| Hyperuricemia | 0.919 (0.879–0.961) | <0.001 |
| Fasting glucose (per 1 mg/dl) | 0.998 (0.997–0.999) | <0.001 |
| Hemoglobin (per 1 g/dl) | 1.016 (1.003–1.030) | 0.019 |
| Triglyceride (per 10 mg/dl) | 1.002 (1.000–1.004) | 0.109 |
| Total cholesterol (per 10 mg/dl) | 0.993 (0.982–1.004) | 0.191 |
| LDL-C (per 1 mg/dl) | 1.001 (1.000–1.002) | 0.143 |
| eGFR (per 1 ml/min/1.73 m2) | 0.999 (0.999–1.000) | 0.099 |
Determinants for self-reported PUD using multivariable logistic regression analysis.
Values expressed as odds ratio and 95% confidence interval (CI). Abbreviations are the same as in Table 1. Adjusted for age, sex, DM and hypertension, smoking and alcohol history, regular exercise habit, systolic BP, BMI, uric acid, fasting glucose, hemoglobin, triglyceride, total cholesterol, LDL-cholesterol, and eGFR. Hyperuricemia was defined as serum uric acid concentration greater than 7.0 and 6.0 mg/dl in the male and female participants, respectively.
Comparisons of the male and female participants with and without self-reported PUD
Table 3 shows the comparisons of the male and female participants with and without self-reported PUD. The male participants with self-reported PUD were older and had higher rates of DM, hypertension, smoking and alcohol consumption, regular exercise, and higher HDL-C, and lower diastolic blood pressure, BMI, uric acid, hyperuricemia prevalence, hemoglobin, triglycerides, LDL-C, and eGFR than those without self-reported PUD (Table 3). The female participants with self-reported PUD were older and had higher prevalence rates of DM, hypertension, alcohol and smoking consumption, regular exercise, and higher SBP, uric acid, fasting glucose, hemoglobin, triglyceride, total cholesterol, and LDL-C, and lower BMI and eGFR than those without self-reported PUD (Table 1).
TABLE 3
| Characteristics | Male (n = 43,698) | Female (n = 77,885) | ||||
| Self-reported PUD (−) (n = 36,494) |
Self-reported PUD (+) (n = 7,204) |
p | Self-reported PUD (−) (n = 67,393) |
Self-reported PUD (+) (n = 10,492) |
p | |
| Age (year) | 49.1 ± 11.4 | 53.8 ± 10.2 | <0.001 | 49.4 ± 10.8 | 52.7 ± 9.9 | <0.001 |
| DM (%) | 6.5 | 8.4 | <0.001 | 4.0 | 5.6 | <0.001 |
| Hypertension (%) | 16.0 | 21.1 | <0.001 | 9.3 | 11.9 | <0.001 |
| Smoking history (%) | 56.3 | 62.8 | <0.001 | 10.1 | 11.8 | <0.001 |
| Alcohol history (%) | 18.2 | 21.4 | <0.001 | 2.8 | 3.2 | 0.017 |
| Regular exercise habits (%) | 41.5 | 46.6 | <0.001 | 39.0 | 43.1 | <0.001 |
| Systolic BP (mmHg) | 126.3 ± 17.3 | 126.7 ± 17.2 | 0.098 | 117.1 ± 18.6 | 117.5 ± 18.1 | 0.017 |
| Diastolic BP (mmHg) | 78.5 ± 11.1 | 78.2 ± 10.7 | 0.024 | 71.2 ± 10.8 | 71.0 ± 10.4 | 0.069 |
| BMI (kg/m2) | 25.5 ± 3.6 | 24.9 ± 3.5 | <0.001 | 23.6 ± 3.8 | 23.5 ± 3.7 | 0.028 |
| Laboratory parameters | ||||||
| Uric acid (mg/dl) | 6.45 ± 1.37 | 6.28 ± 1.35 | <0.001 | 4.86 ± 1.12 | 4.90 ± 1.13 | 0.002 |
| Hyperuricemia (%) | 30.5 | 26.2 | <0.001 | 13.5 | 14.2 | 0.051 |
| Fasting glucose (mg/dl) | 99.3 ± 23.6 | 99.8 ± 22.2 | 0.064 | 93.9 ± 18.9 | 94.8 ± 17.9 | <0.001 |
| Hemoglobin (g/dl) | 15.1 ± 1.2 | 15.0 ± 1.3 | <0.001 | 13.0 ± 1.3 | 13.1 ± 1.2 | <0.001 |
| Triglyceride (mg/dl) | 138.8 ± 121.4 | 133.0 ± 97.7 | <0.001 | 102.5 ± 73.6 | 107.3 ± 80.8 | <0.001 |
| Total cholesterol (mg/dl) | 192.0 ± 35.2 | 191.2 ± 34.5 | 0.080 | 197.4 ± 36.1 | 200.2 ± 35.8 | <0.001 |
| HDL-C (mg/dl) | 47.9 ± 11.1 | 48.5 ± 11.3 | <0.001 | 58.2 ± 13.2 | 58.5 ± 13.7 | 0.093 |
| LDL-C (mg/dl) | 121.9 ± 31.5 | 120.9 ± 31.4 | 0.020 | 120.3 ± 31.9 | 121.9 ± 31.7 | <0.001 |
| eGFR (ml/min/1.73 m2) | 94.1 ± 19.3 | 92.0 ± 20.0 | <0.001 | 109.0 ± 24.5 | 106.2 ± 24.1 | <0.001 |
Clinical characteristics of the study participants classified by the presence of different sex and self-reported PUD.
Abbreviations are the same as in Table 1. Hyperuricemia was defined as serum uric acid concentration greater than 7.0 and 6.0 mg/dl in the male and female participants, respectively.
Association and interaction of hyperuricemia with self-reported PUD in the male and female participants
Table 4 shows the association and interaction of hyperuricemia with self-reported PUD in the male and female participants. The results of multivariable logistic regression analysis with adjustments for the covariates listed in section “Statistical analysis” except sex showed that hyperuricemia was associated with a lower risk of self-reported PUD (OR = 0.890; 95% CI = 0.837–0.947; p < 0.001) in the male participants, but that hyperuricemia was not associated with self-reported PUD (OR = 0.952; 95% CI = 0.893–1.016; p = 0.139) in the female participants. In addition, a significant interaction was found between sex and hyperuricemia on self-reported PUD (p = 0.004) (Table 4).
TABLE 4
| Characteristics | Male (n = 43,698) | Female (n = 77,885) | ||||
| OR | 95% CI | p | OR | 95% CI | p | |
| Age (per 1 year) | 1.039 | 1.036–1.042 | <0.001 | 1.037 | 1.034–1.039 | <0.001 |
| DM | 1.047 | 0.938–1.170 | 0.414 | 1.237 | 1.112–1.376 | <0.001 |
| Hypertension | 1.183 | 1.102–1.270 | <0.001 | 1.140 | 1.060–1.225 | <0.001 |
| Smoking history | 1.226 | 1.161–1.295 | <0.001 | 1.387 | 1.296–1.483 | <0.001 |
| Alcohol history | 1.135 | 1.062–1.212 | <0.001 | 1.084 | 0.959–1.225 | 0.197 |
| Regular exercise habits | 0.928 | 0.879–0.980 | 0.008 | 0.949 | 0.907–0.992 | 0.022 |
| Systolic BP (per 1 mmHg) | 0.995 | 0.993–0.996 | <0.001 | 0.993 | 0.991–0.994 | <0.001 |
| BMI (per 1 kg/m2) | 0.968 | 0.960–0.977 | <0.001 | 0.990 | 0.984–0.997 | 0.004 |
| Laboratory parameters | ||||||
| Hyperuricemia (%) | 0.890 | 0.837–0.947 | <0.001 | 0.952 | 0.893–1.016 | 0.139 |
| Fasting glucose (per 1 mg/dl) | 0.998 | 0.997–0.999 | 0.005 | 0.998 | 0.997–0.999 | 0.005 |
| Hemoglobin (per 1 g/dl) | 1.007 | 0.984–1.029 | 0.565 | 1.026 | 1.008–1.044 | 0.004 |
| Triglyceride (per 10 mg/dl) | 1.000 | 0.997–1.003 | 0.911 | 1.004 | 1.001–1007 | 0.005 |
| Total cholesterol (per 10 mg/dl) | 0.995 | 0.976–1.014 | 0.624 | 0.995 | 0.981–1.008 | 0.432 |
| LDL-C (per 1 mg/dl) | 1.001 | 0.999–1.003 | 0.451 | 1.001 | 0.999–1.002 | 0.468 |
| eGFR (per 1 ml/min/1.73 m2) | 0.999 | 0.998–1.001 | 0.435 | 0.999 | 0.998–1.000 | 0.123 |
Association of factors with self-reported PUD in different sex using multivariable logistic regression analysis.
Values expressed as odds ratio (OR) and 95% confidence interval (CI). Abbreviations are the same as in Table 1. Adjusted for age, DM and hypertension, smoking and alcohol history, regular exercise habit, systolic BP, BMI, hyperuricemia, fasting glucose, hemoglobin, triglyceride, total cholesterol, LDL-cholesterol, and eGFR. Hyperuricemia was defined as serum uric acid concentration greater than 7.0 and 6.0 mg/dl in the male and female participants, respectively.
Discussion
In this large Taiwanese population-based study, we examined the risk factors for self-reported PUD and sex differences in the association between hyperuricemia and self-reported PUD. Our results showed that compared to the female participants, the male participants had a higher prevalence of self-reported PUD. Further, a significant interaction was found between sex and hyperuricemia on self-reported PUD, and hyperuricemia was associated with a low prevalence of self-reported PUD in the male participants, but not in the female participants.
Our finding of a higher prevalence of self-reported PUD in males compared to females (16.5% vs. 13.5%, p < 0.001), male sex (vs. female sex; OR = 1.139; 95% CI = 1.084–1.198; p < 0.001) was significantly associated with self-reported PUD, which is similar to a large-scale, multicenter trial involving over 2,000 patients taking NSAIDs (32). The trial aimed to assess the effectiveness of omeprazole compared to other agents including misoprostol and ranitidine in healing and preventing NSAID-induced ulcers, and the results showed that the incidence of these lesions tended to be higher in in men (62%) compared to women (50%) (32). In addition, duodenal ulcers were more prevalent in men (26%) than in women (8%) (32). In a population-based study involving 204 countries, males had a higher incidence and prevalence of PUD, along with higher mortality and disability-adjusted life years associated with PUD than women in all years from 1990 to 2019 (2). In 2019, there were 3.92 million prevalent cases of PUD in females compared to 4.17 million in males, and the proportion of prevalent cases between males and females was 1:0.94 (2). Possible reasons for the higher prevalence of PUD in males may involve biological and physiological differences between males and females, such as hormonal differences (i.e., the protective effects of estrogen in women) affecting the development of ulcers (33–35).
Another interesting finding is that hyperuricemia was associated with a low prevalence of self-reported PUD in the male participants (OR = 0.890; 95% CI = 0.837–0.947; p < 0.001). This finding provides evidence supporting the protective effect of hyperuricemia against PUD in males. Previous studies have reported a link between hyperuricemia with an increased risk of several systemic diseases, notably gout and various cardiovascular issues (such as hypertension, heart structure and function), dyslipidemia, chronic kidney disease, thyroid disorders, and metabolic syndrome (15–19). Whereas, another study discussing the relationship between uric acid and osteoporosis suggested that hyperuricemia could have a protective effect against neurodegenerative diseases and may reduce the risk of bone fractures by affecting bone mineral density (24). In the narrative review by Otani et al. (36), the authors investigate the complex role of uric acid in neurological disorders. It details how uric acid’s antioxidant properties might confer neuroprotection by scavenging free radicals and inhibiting lipid peroxidation (36). Notably, the review presents evidence indicating that higher uric acid levels might be linked to a decreased risk and slower progression of Parkinson’s disease (36). High uric acid levels might have contributed to the development of higher intelligence and better neurological health in humans by providing significant antioxidant capacity (36, 37). In a randomized, double-blind, placebo-controlled study involving 24 participants, the effects of intravenously administered uric acid on endothelial function were explored (38). Each participant received 1,000 mg of uric acid, vitamin C, vehicle alone, or saline across separate sessions. Forearm blood flow responses to acetylcholine and sodium nitroprusside were measured using venous occlusion plethysmography. The study found that uric acid, like vitamin C, improved endothelial responses to acetylcholine in diabetics and smokers, suggesting that high levels of uric acid could have protective cardiovascular effects in conditions associated with increased oxidative stress (38). In addition, a study conducted in Taiwan of 1,166 patients hospitalized for ischemic stroke found that higher serum uric acid levels were correlated with better neurological outcomes in male patients but not in female patients, especially in those with the large-artery atherosclerosis stroke subtype (22). The study suggested that serum uric acid level might have a neuroprotective role due to its antioxidant properties, which could be particularly beneficial in the context of oxidative stress during acute ischemic stroke (22). In addition, an animal study observed a relationship between the intestinal tract in mice and uric acid (39). In that study, mice were given inosinic acid to create high and moderate levels of serum uric acid. When the mice were given indomethacin, a medication that typically causes enteropathy, those with higher uric acid levels showed less damage and reduced intestinal reactive oxygen species. The authors concluded that elevated levels of uric acid in the mice seemed to protect their intestines from damage (39). It is also mentioned that uric acid significantly influences gut microbiota composition, which plays a key role in its protective effects against enteropathy. Studies have demonstrated that mice with elevated uric acid levels exhibit richer α-diversity and distinct β-diversity in their gut microbiota compared to controls. This more diverse microbiota potentially enhances the gut’s defense against pathogenic bacteria and supports intestinal integrity (39). Hyperuricemia might reduce the risk of PUD due to its strong antioxidant properties, which can mitigate oxidative stress—an underlying factor in the pathogenesis of PUD (39). Oxidative stress can damage gastric mucosal linings (39), and the antioxidant capability of uric acid may help protect against this damage. The study by Wada et al. (39) provides significant insights into the potential protective mechanisms of uric acid against indomethacin-induced enteropathy, particularly focusing on its role within the intestinal lumen. Their findings suggest that luminal uric acid may protect against gastrointestinal damage through antioxidant properties of uric acid and modulation of gut microbiota. Furthermore, the transplantation of fecal microbiota from mice with high uric acid levels into other mice ameliorated indomethacin-induced enteropathy, underscoring the significant role of microbiota in mediating uric acid’s protective effects (39). These findings may partially explain our finding that hyperuricemia was associated with a low prevalence of self-reported PUD in the male participants.
We also found that hyperuricemia was associated with a low prevalence of self-reported PUD in the male participants (OR = 0.890; 95% CI = 0.837–0.947; p < 0.001), whereas this association was not found in the female participants (p = 0.139). The absence of a relationship between high uric acid levels and PUD in women might be due to sex differences in uric acid metabolism and its biological effects (40). Sex differences have been observed in many diseases, including cancer, cardiovascular and liver diseases, and these differences can have a major influence on the clinical presentation, disease progression, and response to treatment (9). The mechanism behind sex differences and sexual dimorphism is considered to be linked to sex hormones (41). Another possible reason may be that women have larger subcutaneous fat stores than men, providing better lipid storage and starvation resistance. Female mitochondria exhibit higher functional capacity and resistance to oxidative damage, reducing the transmission of metabolic disorders (42). Sex differences have also been noted in immune responses, with females exhibiting stronger T cell and humoral immune responses compared to males in adaptive immunity (43). Hormonal differences, especially the role of estrogen, may influence how uric acid affects the body (44), potentially altering the risk and severity of PUD. Moreover, women typically have lower uric acid levels than men due to hormonal regulation and renal excretion, which could account for the lack of association (45). Further research is required to delineate these mechanisms more clearly.
The key strength of this population-based investigation is that we included a large study cohort of adults living in the community. Several limitations should also be mentioned. First, as this was a cross-sectional study, we were unable to evaluate the duration of illness, and consequently we were unable to evaluate causal relationships between hyperuricemia and PUD. Longitudinal studies to evaluate the risk of incident PUD are warranted. Second, the presence of PUD was assessed using self-reported questionnaires, and therefore the severity and type of PUD were unknown. Nevertheless, Wu et al. (46) reported a moderate concordance between claims records and self-reported renal diseases in Taiwan. Third, some medications may influence the value of uric acid, and result in PUD were lacking in TWB, which may influence our analysis. Finally, the Chinese ethnicity of our participants may limit the applicability of our findings to other groups.
Conclusion
In conclusion, we identified a higher prevalence of self-reported PUD in the male participants than in the female participants. Furthermore, we found a significant interaction between sex and hyperuricemia on self-reported PUD. Hyperuricemia was associated with a low prevalence of self-reported PUD in the male participants but not in the female participants in this large Taiwanese population study. Further studies are needed to clarify the mechanisms behind these observations and verify the potential protective role of hyperuricemia on the development of PUD.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by the Institutional Review Board of Kaohsiung Medical University Hospital (protocol code KMU-HIRB-E(I)-20210058 and 8 April 2021 approval). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
C-SY: Writing – original draft. J-HG: Conceptualization, Data curation, Methodology, Writing – review & editing. P-YW: Conceptualization, Data curation, Writing – review & editing. J-CH: Conceptualization, Data curation, Writing – review & editing. H-MH: Conceptualization, Data curation, Writing – review & editing. S-CC: Conceptualization, Data curation, Formal analysis, Methodology, Writing – review & editing. C-HK: Conceptualization, Data curation, Supervision, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
Malik TF Gnanapandithan K Singh K. Peptic ulcer disease. Treasure Island, FL: StatPearls (2022).
2.
Xie X Ren K Zhou Z Dang C Zhang H . The global, regional and national burden of peptic ulcer disease from 1990 to 2019: A population-based study.BMC Gastroenterol. (2022) 22:58. 10.1186/s12876-022-02130-2
3.
Lu CL Chang SS Wang SS Chang FY Lee SD . Silent peptic ulcer disease: Frequency, factors leading to “silence,” and implications regarding the pathogenesis of visceral symptoms.Gastrointest Endosc. (2004) 60:34–8. 10.1016/s0016-5107(04)01311-2
4.
Prescrire International. Helicobacter pylori and gastric or duodenal ulcer. Prescrire Int. (2016) 25:18–23.
5.
Melcarne L Garcia-Iglesias P Calvet X . Management of NSAID-associated peptic ulcer disease.Expert Rev Gastroenterol Hepatol. (2016) 10:723–33.
6.
Lau JY Sung J Hill C Henderson C Howden CW Metz DC . Systematic review of the epidemiology of complicated peptic ulcer disease: Incidence, recurrence, risk factors and mortality.Digestion. (2011) 84:102–13.
7.
Lee SP Sung IK Kim JH Lee SY Park HS Shim CS . Risk factors for the presence of symptoms in peptic ulcer disease.Clin Endosc. (2017) 50:578–84.
8.
Hooi JKY Lai WY Ng WK Suen MMY Underwood FE Tanyingoh D et al Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. (2017) 153:420–9.
9.
Mauvais-Jarvis F Bairey Merz N Barnes PJ Brinton RD Carrero JJ DeMeo DL et al Sex and gender: Modifiers of health, disease, and medicine. Lancet. (2020) 396:565–82.
10.
Lin KJ Garcia Rodriguez LA Hernandez-Diaz S . Systematic review of peptic ulcer disease incidence rates: Do studies without validation provide reliable estimates?Pharmacoepidemiol Drug Saf. (2011) 20:718–28. 10.1002/pds.2153
11.
Chmiela M Kupcinskas J . Review: Pathogenesis of Helicobacter pylori infection.Helicobacter. (2019) 24:e12638.
12.
Benn CL Dua P Gurrell R Loudon P Pike A Storer RI et al Physiology of hyperuricemia and urate-lowering treatments. Front Med (Lausanne). (2018) 5:160. 10.3389/fmed.2018.00160
13.
Si K Wei C Xu L Zhou Y Lv W Dong B et al Hyperuricemia and the risk of heart failure: Pathophysiology and therapeutic implications. Front Endocrinol (Lausanne). (2021) 12:770815. 10.3389/fendo.2021.770815
14.
Kanellis J Feig DI Johnson RJ . Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease? An old controversy renewed.Nephrology (Carlton). (2004) 9:394–9. 10.1111/j.1440-1797.2004.00336.x
15.
Yu KH Chen DY Chen JH Chen SY Chen SM Cheng TT et al Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int J Rheum Dis. (2018) 21:772–87. 10.1111/1756-185X.13266
16.
Chiu TH Wu PY Huang JC Su HM Chen SC Chang JM et al hyperuricemia is associated with left ventricular dysfunction and inappropriate left ventricular mass in chronic kidney disease. Diagnostics (Basel). (2020) 10:514. 10.3390/diagnostics10080514
17.
Maloberti A Mengozzi A Russo E Cicero AFG Angeli F Agabiti Rosei E et al Cardiovascular risk of the italian society of, the results of the urrah (uric acid right for heart health) project: A focus on hyperuricemia in relation to cardiovascular and kidney disease and its role in metabolic dysregulation. High Blood Press Cardiovasc Prev. (2023) 30:411–25. 10.1007/s40292-023-00602-4
18.
Wei CY Sun CC Wei JC Tai HC Sun CA Chung CF et al Association between hyperuricemia and metabolic syndrome: An epidemiological study of a labor force population in Taiwan. Biomed Res Int. (2015) 2015:369179. 10.1155/2015/369179
19.
Segura J Campo C Ruilope L . How relevant and frequent is the presence of mild renal insufficiency in essential hypertension?J Clin Hypertens. (2002) 4:332–6. 10.1111/j.1524-6175.2002.01003.x
20.
Latourte A Dumurgier J Paquet C Richette P . Hyperuricemia, gout, and the brain-an update.Curr Rheumatol Rep. (2021) 23:82. 10.1007/s11926-021-01050-6
21.
Wang L Tan Z Wang FY Wu WP Wu JC . Gout/hyperuricemia reduces the risk of Alzheimer’s disease: A meta-analysis based on latest evidence.Brain Behav. (2023) 13:e3207.
22.
Wang YF Li JX Sun XS Lai R Sheng WL . High serum uric acid levels are a protective factor against unfavourable neurological functional outcome in patients with ischaemic stroke.J Int Med Res. (2018) 46:1826–38. 10.1177/0300060517752996
23.
Tang X Song ZH Cardoso MA Zhou JB Simo R . The relationship between uric acid and brain health from observational studies.Metab Brain Dis. (2022) 37:1989–2003. 10.1007/s11011-022-01016-2
24.
Lin KM Lu CL Hung KC Wu PC Pan CF Wu CJ et al The paradoxical role of uric acid in osteoporosis. Nutrients. (2019) 11:2111.
25.
Ahn SH Lee SH Kim BJ Lim KH Bae SJ Kim EH et al Higher serum uric acid is associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in healthy postmenopausal women. Osteoporos Int. (2013) 24:2961–70. 10.1007/s00198-013-2377-7
26.
Yin H Liu N Chen J . The role of the intestine in the development of hyperuricemia.Front Immunol. (2022) 13:845684. 10.3389/fimmu.2022.845684
27.
Chen CH Yang JH Chiang CWK Hsiung CN Wu PE Chang LC et al Population structure of Han Chinese in the modern Taiwanese population based on 10,000 participants in the Taiwan Biobank project. Hum Mol Genet. (2016) 25:5321–31. 10.1093/hmg/ddw346
28.
Fan CT Hung TH Yeh CK . Taiwan regulation of biobanks.J Law Med Ethics. (2015) 43:816–26.
29.
Vickery S Stevens PE Dalton RN van Lente F Lamb EJ . Does the ID-MS traceable MDRD equation work and is it suitable for use with compensated Jaffe and enzymatic creatinine assays?Nephrol Dial Transplant. (2006) 21:2439–45. 10.1093/ndt/gfl249
30.
Ministry of Education. Physical fitness 333 plan. Taipei: Ministry of Education (1999).
31.
Lee JW Kwon BC Choi HG . Analyses of the relationship between hyperuricemia and osteoporosis.Sci Rep. (2021) 11:12080.
32.
Hawkey CJ Wilson I Naesdal J Langstrom G Swannell AJ Yeomans ND . Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users.Gut. (2002) 51:344–50. 10.1136/gut.51.3.344
33.
Truelove SC . Stilboestrol, phenobarbitone, and diet in chronic duodenal ulcer. A factorial therapeutic trial.Br Med J. (1960) 2:559–66. 10.1136/bmj.2.5198.559
34.
Shorrock CJ Langman MJ . Nonsteroidal anti-inflammatory drug-induced gastric damage: Epidemiology.Dig Dis. (1995) 13:3–8.
35.
Kurata JH Haile BM Elashoff JD . Sex differences in peptic ulcer disease.Gastroenterology. (1985) 88:96–100.
36.
Otani N Hoshiyama E Ouchi M Takekawa H Suzuki K . Uric acid and neurological disease: A narrative review.Front Neurol. (2023) 14:1164756. 10.3389/fneur.2023.1164756
37.
Alvarez-Lario B Macarron-Vicente J . Uric acid and evolution.Rheumatology. (2010) 49:2010–5.
38.
Waring WS McKnight JA Webb DJ Maxwell SR . Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers.Diabetes. (2006) 55:3127–32. 10.2337/db06-0283
39.
Wada A Higashiyama M Kurihara C Ito S Tanemoto R Mizoguchi A et al Protective effect of luminal uric acid against indomethacin-induced enteropathy: role of antioxidant effect and gut microbiota. Dig Dis Sci. (2022) 67:121–33. 10.1007/s10620-021-06848-z
40.
Qian T Sun H Xu Q Hou X Hu W Zhang G et al Hyperuricemia is independently associated with hypertension in men under 60 years in a general Chinese population. J Hum Hypertens. (2021) 35:1020–8. 10.1038/s41371-020-00455-7
41.
Mittendorfer B . Insulin resistance: Sex matters.Curr Opin Clin Nutr Metab Care. (2005) 8:367–72.
42.
Mauvais-Jarvis F . Sex differences in energy metabolism: Natural selection, mechanisms and consequences.Nat Rev Nephrol. (2024) 20:56–69.
43.
Klein SL Flanagan KL . Sex differences in immune responses.Nat Rev Immunol. (2016) 16:626–38.
44.
Eun Y Kim IY Han K Lee KN Lee DY Shin DW et al Association between female reproductive factors and gout: A nationwide population-based cohort study of 1 million postmenopausal women. Arthritis Res Ther. (2021) 23:304. 10.1186/s13075-021-02701-w
45.
Anton FM Garcia Puig J Ramos T Gonzalez P Ordas J . Sex differences in uric acid metabolism in adults: Evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate.Metabolism. (1986) 35:343–8. 10.1016/0026-0495(86)90152-6
46.
Wu CS Lai MS Gau SS Wang SC Tsai HJ . Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan.PLoS One. (2014) 9:e112257. 10.1371/journal.pone.0112257
Summary
Keywords
sex difference, hyperuricemia, self-reported peptic ulcer disease, Taiwan Biobank, Risk factors
Citation
Yang C-S, Geng J-H, Wu P-Y, Huang J-C, Hu H-M, Chen S-C and Kuo C-H (2024) Sex difference in the associations among hyperuricemia with self-reported peptic ulcer disease in a large Taiwanese population study. Front. Med. 11:1383290. doi: 10.3389/fmed.2024.1383290
Received
07 February 2024
Accepted
29 May 2024
Published
10 June 2024
Volume
11 - 2024
Edited by
Lihua Duan, Jiangxi Provincial People’s Hospital, China
Reviewed by
Alessandro Maloberti, University of Milano-Bicocca, Italy
Chih-Chung Shiao, Saint Mary’s Hospital Luodong, Taiwan
Updates
Copyright
© 2024 Yang, Geng, Wu, Huang, Hu, Chen and Kuo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Szu-Chia Chen, scarchenone@yahoo.com.twChao-Hung Kuo, kjh88kmu@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.